Scientists have demonstrated that a small-molecule inhibitor can preserve fertility in mice, when administered as a co-treatment with conventional chemotherapy.
A Northwestern Medicine study has established a new safety index for a common group of chemotherapy drugs, by using a stem cell model to screen such therapies for cardiotoxicity.
In research published in Nature Medicine, Northwestern Medicine scientists have found a molecule that stops the growth of an aggressive pediatric brain tumor for which there is no current treatment.
A phase 1 clinical trial of venetoclax and rituximab combination therapy was shown to be an effective chemo-free treatment option for patients with difficult-to-treat chronic lymphocytic leukemia.
A newly identified biomarker may predict treatment response in patients with chronic myelogenous leukemia, according to a Northwestern Medicine study.
In recent Northwestern Medicine clinical trials, an experimental drug improved survival rates for patients with advanced midgut neuroendocrine tumors compared to a standard therapy.
A surgical procedure called a pelvic exenteration may be curative for more than half of women with a form of advanced cervical cancer who have failed other treatments.
Northwestern Medicine scientists have identified the unique targets of two enzymes that activate ubiquitination, a key modification of proteins that controls a variety of cellular processes.
A novel national trial for people with no established alternative to treat their rare cancers is being co-led by Northwestern Medicine investigators, who helped conceive of and develop the project.
The addition of the drug cetuximab to standard chemoradiation reduced the incidence of relapse for patients with anal cancer, but was associated with significant adverse effects, according to recent Northwestern Medicine clinical trials.